These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 18657577

  • 1. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
    Mihara T, Iwashita A, Matsuoka N.
    Behav Brain Res; 2008 Dec 12; 194(2):152-61. PubMed ID: 18657577
    [Abstract] [Full Text] [Related]

  • 2. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition.
    Mihara T, Mihara K, Yarimizu J, Mitani Y, Matsuda R, Yamamoto H, Aoki S, Akahane A, Iwashita A, Matsuoka N.
    J Pharmacol Exp Ther; 2007 Nov 12; 323(2):708-19. PubMed ID: 17684118
    [Abstract] [Full Text] [Related]

  • 3. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 4. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Exp Neurol; 2010 Dec 28; 226(2):320-7. PubMed ID: 20843474
    [Abstract] [Full Text] [Related]

  • 5. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 6. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P.
    Exp Neurol; 2008 May 10; 211(1):172-9. PubMed ID: 18321484
    [Abstract] [Full Text] [Related]

  • 7. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M.
    Neuropharmacology; 2010 Mar 10; 58(3):613-23. PubMed ID: 19951715
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
    Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P.
    Pharmacol Biochem Behav; 2004 Nov 10; 79(3):391-400. PubMed ID: 15582011
    [Abstract] [Full Text] [Related]

  • 10. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.
    Mov Disord; 2006 Dec 10; 21(12):2090-5. PubMed ID: 16991143
    [Abstract] [Full Text] [Related]

  • 11. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R, Sindhu KM, Chandra G, Mohanakumar KP.
    Behav Brain Res; 2005 Sep 08; 163(2):159-67. PubMed ID: 15941598
    [Abstract] [Full Text] [Related]

  • 12. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R, Jackson MJ, Rose S, Stockwell K, Tayarani-Binazir KA, Zubair M, Smith LA, Jenner P, Lees AJ.
    Mov Disord; 2007 Apr 15; 22(5):715-9. PubMed ID: 17373723
    [Abstract] [Full Text] [Related]

  • 13. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P.
    Mov Disord; 2010 Feb 15; 25(3):377-84. PubMed ID: 20108359
    [Abstract] [Full Text] [Related]

  • 14. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Mov Disord; 2010 Oct 15; 25(13):2059-66. PubMed ID: 20721904
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
    Löschmann PA, De Groote C, Smith L, Wüllner U, Fischer G, Kemp JA, Jenner P, Klockgether T.
    Exp Neurol; 2004 May 15; 187(1):86-93. PubMed ID: 15081591
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T.
    Eur J Pharmacol; 2015 Jan 15; 747():160-5. PubMed ID: 25499739
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L, De Salvia M, Jenner P, Marsden CD.
    Mov Disord; 1996 Mar 15; 11(2):125-35. PubMed ID: 8684381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.